These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1547341)

  • 1. Antithrombin-III-Stockholm: a codon 392 (Gly----Asp) mutation with normal heparin binding and impaired serine protease reactivity.
    Blajchman MA; Fernandez-Rachubinski F; Sheffield WP; Austin RC; Schulman S
    Blood; 1992 Mar; 79(6):1428-34. PubMed ID: 1547341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity.
    Devraj-Kizuk R; Chui DH; Prochownik EV; Carter CJ; Ofosu FA; Blajchman MA
    Blood; 1988 Nov; 72(5):1518-23. PubMed ID: 3179438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombin III Kumamoto II; a single mutation at Arg393-His increased the affinity of antithrombin III for heparin.
    Okajima K; Abe H; Wagatsuma M; Okabe H; Takatsuki K
    Am J Hematol; 1995 Jan; 48(1):12-8. PubMed ID: 7832187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombin III Nagasaki (Ser116-Pro): a heterozygous variant with defective heparin binding associated with thrombosis.
    Okajima K; Abe H; Maeda S; Motomura M; Tsujihata M; Nagataki S; Okabe H; Takatsuki K
    Blood; 1993 Mar; 81(5):1300-5. PubMed ID: 8443391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa.
    Austin RC; Rachubinski RA; Ofosu FA; Blajchman MA
    Blood; 1991 May; 77(10):2185-9. PubMed ID: 2029579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The N-terminal domain of antithrombin-III is essential for heparin binding and complex-formation with, but not cleavage by, alpha-thrombin.
    Austin RC; Sheffield WP; Rachubinski RA; Blajchman MA
    Biochem J; 1992 Mar; 282 ( Pt 2)(Pt 2):345-51. PubMed ID: 1546950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin.
    Ireland H; Lane DA; Thompson E; Walker ID; Blench I; Morris HR; Freyssinet JM; Grunebaum L; Olds R; Thein SL
    Br J Haematol; 1991 Sep; 79(1):70-4. PubMed ID: 1911389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").
    Sambrano JE; Jacobson LJ; Reeve EB; Manco-Johnson MJ; Hathaway WE
    J Clin Invest; 1986 Mar; 77(3):887-93. PubMed ID: 3512602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissociation of heparin-dependent thrombin and factor Xa inhibitory activities of antithrombin-III by mutations in the reactive site.
    Theunissen HJ; Dijkema R; Grootenhuis PD; Swinkels JC; de Poorter TL; Carati P; Visser A
    J Biol Chem; 1993 Apr; 268(12):9035-40. PubMed ID: 8473344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression in a cell-free system of normal and variant forms of human antithrombin III. Ability to bind heparin and react with alpha-thrombin.
    Austin RC; Rachubinski RA; Fernandez-Rachubinski F; Blajchman MA
    Blood; 1990 Oct; 76(8):1521-9. PubMed ID: 2207328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the antithrombin III Kyoto mutation by restriction fragment length polymorphism analysis.
    Masuda H; Tsuji H; Nakagawa K; Nakahara Y; Kitamura H; Ogasahara Y; Nakagawa M
    Int J Hematol; 1995 Jun; 61(4):197-204. PubMed ID: 8547608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Important role of arginine 129 in heparin-binding site of antithrombin III. Identification of a novel mutation arginine 129 to glutamine.
    Gandrille S; Aiach M; Lane DA; Vidaud D; Molho-Sabatier P; Caso R; de Moerloose P; Fiessinger JN; Clauser E
    J Biol Chem; 1990 Nov; 265(31):18997-9001. PubMed ID: 2229057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombin Vicenza, Ala 384 to Pro (GCA to CCA) mutation, transforming the inhibitor into a substrate.
    Caso R; Lane DA; Thompson EA; Olds RJ; Thein SL; Panico M; Blench I; Morris HR; Freyssinet JM; Aiach M
    Br J Haematol; 1991 Jan; 77(1):87-92. PubMed ID: 1998601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding.
    Tripodi A; Krachmalnicoff A; Mannucci PM
    Thromb Haemost; 1986 Dec; 56(3):349-52. PubMed ID: 3563966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of the P2 glycine of antithrombin in target proteinase specificity, heparin activation, and the efficiency of proteinase trapping as revealed by a P2 Gly --> Pro mutation.
    Chuang YJ; Gettins PG; Olson ST
    J Biol Chem; 1999 Oct; 274(40):28142-9. PubMed ID: 10497166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
    Jørgensen M; Petersen LC; Thorsen S
    J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site-directed mutagenesis of alanine-382 of human antithrombin III.
    Austin RC; Rachubinski RA; Blajchman MA
    FEBS Lett; 1991 Mar; 280(2):254-8. PubMed ID: 2013320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substitution of Gly-548 to Ala in the substrate binding pocket of prothrombin Perijá leads to the loss of thrombin proteolytic activity.
    Sekine O; Sugo T; Ebisawa K; Umeyama H; Iwahana H; Ruiz-Sáez A; de Bosch N; Matsudai M
    Thromb Haemost; 2002 Feb; 87(2):282-7. PubMed ID: 11858488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombin Padua. I: Impaired heparin binding caused by an Arg47 to his (CGT to CAT) substitution.
    Caso R; Lane DA; Thompson E; Zangouras D; Panico M; Morris H; Olds RJ; Thein SL; Girolami A
    Thromb Res; 1990 Apr; 58(2):185-90. PubMed ID: 2349545
    [No Abstract]   [Full Text] [Related]  

  • 20. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto.
    Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K
    Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.